Early stimulated immune responses predict clinical disease severity in hospitalized COVID-19 patients.

ABSTRACT:

Background

The immune pathogenesis underlying the diverse clinical course of COVID-19 is poorly understood. Currently, there is an unmet need in daily clinical practice for early biomarkers and improved risk stratification tools to help identify and monitor COVID-19 patients at risk of severe disease.

Methods

We performed longitudinal assessment of stimulated immune responses in 30 patients hospitalized with COVID-19. We used the TruCulture whole-blood ligand-stimulation assay applying standardized stimuli to activate distinct immune pathways, allowing quantification of cytokine responses. We further characterized immune cell subsets by flow cytometry and used this deep immunophenotyping data to map the course of clinical disease within and between patients.

Results

H

SUBMITTER: Svanberg R 

PROVIDER: S-EPMC9466310 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature